Moving forward, clinicians should consider screening for anti-AP3B2 antibodies in patients presenting with SCD-like manifestations who exhibit poor responsiveness to vitamin B12 therapy. The gene discussed is AP3B2; the disease is Schnyder corneal dystrophy.